Drug Profile
Research programme: cancer therapeutics - Genexine
Alternative Names: GX-02; GX-06Latest Information Update: 02 Apr 2018
Price :
$50
*
At a glance
- Originator Genexine
- Class CAR-NK cell therapies; Immunotherapies
- Mechanism of Action Immunomodulators; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Brain cancer; Breast cancer; Haematological malignancies; Skin cancer
Most Recent Events
- 02 Apr 2018 Discontinued - Preclinical for Haematological malignancies in South Korea (unspecified route) (Genexine pipeline, March 2018)
- 28 Mar 2018 Discontinued - Preclinical for Brain cancer in South Korea (Parenteral) (Genexine pipeline, March 2018)
- 28 Mar 2018 Discontinued - Preclinical for Breast cancer in South Korea (Parenteral) (Genexine pipeline, March 2018)